Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
Go back to Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer| VERASTEM SHS (NASDAQ: VSTM) | Delayed: 8.08 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.08 | 52 Week High | $2.43 | |||
| Open | $8.08 | 52 Week Low | $1.05 | |||
| Day High | $8.08 | P/E | N/A | |||
| Day Low | $8.08 | EPS | $-1.79 | |||
| Volume | 512 | |||||
